The present disclosure provides a dual delayed release oral pharmaceutical composition of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof. The disclosed dual delayed release pharmaceutical composition can incorporate two pulsatile release formulations (a) and (b), wherein formulation (a) can include: (i) a core particle comprising dexlansoprazole or a pharmaceutically acceptable salt or a hydrate thereof, and (ii) a p H-dependent release-controlled layer； and formulation (b) can include: (i) a core particle comprising dexlansoprazole or a pharmaceutically acceptable salt or a hydrate thereof, (ii) a p H-independent release-controlled layer, and (iii) a p H-dependent release-controlled layer.
